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Background: Quadriceps muscle fiber atrophy and a loss of oxidative type I muscle fibers and mito-
chondrial content often occur in chronic obstructive pulmonary disease (COPD), which adversely affects
exercise performance. Sarcopenia is an age-related syndrome characterized by wasting and weakness of
muscle mass. We recently showed in a large cohort of patients that COPD-related sarcopenia, in
particular in male patients, was not only associated with impaired quadriceps muscle strength but also
with decreased exercise performance endurance, which could imply involvement of altered muscle fiber
type composition. Hence, we hypothesized that both the fiber atrophy and loss of oxidative muscle fibers
are more pronounced in sarcopenic compared with nonsarcopenic patients with COPD.
Objective: The objective of this study was to investigate quadriceps muscle fiber-type characteristics in
relation to presence of sarcopenia in patients with COPD and in healthy age-matched controls.
Design: For this retrospective cross-sectional study, body composition (assessed by dual-energy x-ray
absorptiometry) and quadriceps muscle biopsy (fiber type distribution and sizes) data were collected
from 45 patients with COPDs (aged 42e77 years) and 52 healthy controls (aged 50e77 years). Sarcopenia
was based on assessment of appendicular skeletal muscle mass index.
Results: Sarcopenia was found in 5.8% of healthy controls and in 31.1% of patients with COPD (P < .01). The
proportion of oxidative type I fibers and size of type IIx muscle fibers were decreased in patients with
COPD, and the sarcopenic subgroup showed a further decreased proportion as well as a lower size of type
I fibers.
Conclusions: Type I muscle fiber proportion is lower in sarcopenic compared with nonsarcopenic patients
with COPD. Longitudinal studies may elucidate if the loss of muscle oxidative phenotype drives or ac-
celerates the process of muscle wasting.
 2016 AMDA e The Society for Post-Acute and Long-Term Care Medicine.Muscle wasting is a major hallmark of patients with chronic
obstructive pulmonary disease (COPD) besides impaired lung function
and contributes to impaired exercise capacity,1 decreased health sta-
tus,2 and increased mortality.3,4 Alongside the development and
positioning of new radiographic measurements of body composition
as integrated part of disease phenotyping, nutritional assessment hasby the Lung Foundation
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te and Long-Term Care Medicine.shifted from a body weight-centered to a body composition-centered
approach. Recently, the European Respiratory Society taskforce on
Nutritional assessment and therapy in COPD5 proposed dual energy x-
ray absorptiometry as the most appropriate method for body
composition analysis in COPD, as it allows for screening of osteopo-
rosis combined with assessment of fat mass (FM) and fat-free mass
(FFM) at regional levels in addition to whole body level. Assessment of
the appendicular skeletal muscle mass index (ASMI) traditionally
originates from identification of age-related low muscle mass in
elderly populations, a syndrome described as sarcopenia.6 Its appli-
cation is relatively new in COPD, but might in theory be highly rele-
vant as COPD is suggested as disease of accelerated aging.7 Indeed, we
recently identified sarcopenia in the majority of Dutch patients with
COPD eligible for pulmonary rehabilitation across all body mass index
(BMI) categories.8 Moreover, in this large cohort of patients (n ¼ 505),
we demonstrated that low ASMI was not only associated with
C. van de Bool et al. / JAMDA 17 (2016) 415e420416impaired quadriceps muscle strength but, in particular in men, also
with decreased cycle exercise endurance and walking distance.
Whereas decreased muscle strength directly results from loss of pe-
ripheral skeletal muscle mass,9 this does not apply for the loss of
endurance, which is rather associated with loss of oxidative pheno-
type.10 Consequently, it could be hypothesized that sarcopenia in
COPD is characterized by intrinsic muscular alterations as well. In
COPD, consistent intrinsic alterations in peripheral skeletal muscles
have indeed been described.11 More specifically, quadriceps muscle in
advanced COPD is characterized by predominant atrophy of type IIx
fibers12 as well as a loss of oxidative phenotype (ie, a shift from
oxidative type I to glycolytic II muscle fibers).13 Furthermore, van den
Borst et al14 previously demonstrated that loss of quadriceps oxidative
phenotype and decreased quadriceps endurance was already present
in patients with mild-to-moderate COPD in the absence of muscle and
fiber atrophy.
These alterations culminate in reduced muscle endurance, but in
addition, could also drive or accelerate muscle wasting because the
loss of muscle oxidative phenotype may render muscle in COPD less
energy efficient, and (the remaining) type II fibers are more sensitive
to atrophying disease-related triggers.15e17 Moreover, intrinsic ab-
normalities in peripheral muscle seem more aggravated in emphy-
sematous patients who are also more susceptible to weight loss.18e20
In addition, Gouzi et al21 recently identified an atrophic cluster of
patients with COPD with reduced BMI, FFMI, type I fiber proportion,
and fiber cross-sectional area (CSA) using an unsupervised clustering
method.
Although assessment of muscle fiber alterations is crucial for un-
derstanding the process of muscle wasting in COPD, data is lacking on
differences in muscle fiber-type characteristics between sarcopenic
and nonsarcopenic patients with COPD. Therefore, the aim of this
retrospective study was to compare quadriceps muscle fiber-type
characteristics in relation to sarcopenia6 in patients with COPD and
in healthy controls. We hypothesize that muscle fiber atrophy and loss
of oxidative muscle fibers are more pronounced in the sarcopenic
COPD phenotype.Methods
Participants
The studied population consisted of 45 clinically stable patients
with COPD and 52 healthy controls. All patients were recruited from
the outpatient clinic of the Maastricht University Medical Centerþ
(Maastricht, The Netherlands) and via local newspapers advertise-
ment. Exclusion criteria comprised use of long-term oxygen therapy
or oral prednisolone, acute exacerbation with hospital admission in
the previous 4e8 weeks, or rehabilitation in the previous 6 months.
Patients with known comorbidities as diabetes, recent cardiovas-
cular event, inflammatory bowel disease, obstructive sleep apnea,
thyroid disease, and cancer were carefully excluded because of po-
tential interference with study outcomes. Healthy controls were
recruited via local newspaper advertisement. Absence of diseases
was verified through history-taking by a physician, and absence of
airflow limitation was verified by pulmonary function tests. All
patients participated in 1 out of 3 cross-sectional studies of which
data has been previously published.12,14,22 Participants were
included in 1996-1997, July 2007-July 2010, and March 2009-
April 2010.Ethics
The procedures followed were in accordance with the ethical
standards of the responsible institutional or regional committee onhuman experimentation or in accordance with the Helsinki Declara-
tion of 1975 as revised in 1983.
Lung Function Measurement
In accordance with the latest Global Initiative for Chronic
Obstructive Lung Disease (GOLD) guidelines,23 standardized equip-
ment (Masterlab, Jaeger, Germany) was used to assess post-
bronchodilator forced expiratory volume in 1 second (FEV1) and
forced vital capacity. Diffusion capacity of carbon monoxide was
assessed by single-breathmethod. All obtained values were expressed
as percentages of the predicted value, by comparison with age and
gender-specific reference values.24
Body Composition and Muscle Phenotyping
Total body height was measured to the nearest 0.5 cmwith a wall-
mounted stadiometer and total body weight to the nearest 0.1 kg
using a weighing scale. BMI was calculated as weight/height2 (kg/m2).
Body compositionwas measured by dual energy x-ray absorptiometry
(Lunar Prodigy System, GE Healthcare, Madison, WI; Hologic Discov-
ery, Hologic, Bedford, MA). Fat-free mass index (FFMI) was calculated
by dividing FFM (leanmassþ bonemineral content) by height2 and fat
mass by subtracting FFM from body weight. Sarcopenia was defined
according to cut-offs for ASMI (<7.23 kg/m2 for men; <5.67 kg/m2 for
women).6
Muscle Fiber Typing
Quadriceps muscle biopsy analyses have previously been
described in detail for the 3 individual studies.12,14,22 In short, needle
biopsies were obtained from the vastus lateralis under local anes-
thesia. Sampleswere frozen inmelting isopentane (precooled in liquid
nitrogen) and serial 5 mm cryosections were cut. A combination of
myosin ATPase-activity staining and immunohistochemistry (anti-
bodies against different myosin heavy chain isoforms) was applied to
determine fiber type proportions and fiber cross-sectional areas using
imaging software. All samples were analyzed within a year after
collection.
Statistical Analyses
The Statistical Package for Social Sciences version 20.0 (SPSS, Inc,
Chicago, IL) was used to perform statistical analyses. Normal distri-
bution was assed using the Shapiro-Wilk test. Discrete variables were
compared by the c2 test and presented as percentages. Continuous
variables were presented as median  interquartile range (charac-
teristics) or mean  standard error (muscle fiber composition) and
were compared between 2 groups by the Student t-test for indepen-
dent samples (parametric data) or Mann-Whitney test (nonpara-
metric data), and compared between more than 2 groups by 1-way
analysis of variance (parametric data) or Kruskal-Wallis test
(nonparametric data). Two-sided P values of <.05 were considered
statistically significant.
Because of a too small number of female participants, we could not
perform separate analyses for males and females. Nonetheless, sepa-




Both the COPD and healthy control groups consistedmostly of men
(64.6% and 67.9%; P ¼ .723). The majority of patients with COPD had
Table 1
Participant Characteristics
Nonsarcopenic Control (n ¼ 49) Nonsarcopenic COPD (n ¼ 31) Sarcopenic COPD (n ¼ 14)
General characteristics
Male, % 65.3 51.6 92.9*
Age, years 64.0 (59.5e67.0) 65.0 (61.0e69.0) 68.0 (66.8e74.3)y
FEV1, %predicted 112.8 (103.9e123.8) 57.3 (45.8e69.5)y 42.1 (33.0e49.3)*,y
FVC, %predicted 121.8 (113.8e135.4) 103.0 (83.5e116.3)y 86.4 (76.1e117.5)y
FEV1/FVC, % 92.5 (86.6e98.7) 59.3 (48.2e67.7)y 42.3 (36.5e46.8)*,y
DlCO, %predicted 104.2 (90.2e120.3) 55.4 (40.0e67.8)y 42.2 (35.6e70.1)y
GOLD I/II/III/IV, % 10/50/36.7/3.3 0/14.3/71.4/14.3*
Body composition
Height, cm 173.0 (166.3e178.8) 168.0 (158.0e175.0)y 171.9 (165.2e176.6)
BMI, kg/m2 25.5 (23.3e28.2) 25.8 (23.6e27.8) 23.5 (20.6e25.7)*,y
FFMI, kg/m2 19.0 (17.2e20.3) 18.2 (15.8e19.4) 16.8 (16.2e17.5)*,y
ASMI, kg/m2 8.2 (6.9e8.7) 7.3 (6.3e7.9)y 7.0 (6.5e7.1)y
FMI, kg/m2 6.0 (4.8e8.3) 7.2 (5.8e10.0) 6.3 (3.5e7.7)*
Fat percentage, % 25.1 (19.1e30.6) 28.7 (24.1e37.0)y 26.4 (19.5e31.2)
DlCO, diffusion capacity of carbon monoxide; FVC, forced vital capacity; IQR, interquartile range.
Results presented as median (IQR).
*Statistically different from nonsarcopenic patients with COPD.
yStatistically different from nonsarcopenic controls.
C. van de Bool et al. / JAMDA 17 (2016) 415e420 417moderate to severe impaired lung function, as 6.4% of patients were
classified in GOLD stage I, 36.2% in GOLD stage II, 48.9% in GOLD stage
III, and 8.5% in GOLD stage IV.
Applying the gender-specific cut-offs for ASMI revealed presence
of sarcopenia in 3 male healthy controls, 1 female patient with COPD,
and 13 male patients with COPD, resulting in a total of 5.8% of healthy
controls, compared with 31.1% in patients with COPD (P < .01). In
males, 8.6% of control participants were sarcopenic, compared with
44.8% in patients with COPD (P < .01). Healthy controls with sarco-
penia were excluded in further analyses because of the low number of
participants.
Table 1 shows the participant characteristics per metabolic
phenotype. Sarcopenic patients with COPDs were of similar age as
nonsarcopenic patients, but were slightly older compared with the
nonsarcopenic healthy controls (68 vs 64 years of age; P < .001). In
addition, airflow limitation was more pronounced in sarcopenia
compared with nonsarcopenic patients with COPD (FEV1 42.1% pre-
dicted vs FEV1 57.3% predicted). However, age and FEV1 were no sig-
nificant predictors for ASMI in a regression model, whereas
participant group (control or COPD) significantly predicted ASMI
(P < .01). Nonsarcopenic patients with COPD had a higher fat per-
centage compared with nonsarcopenic controls. In line with a lower
ASMI, sarcopenic patients with COPD showed a lower BMI, FFMI, and
FMI than nonsarcopenic patients with COPD. Similar results were
found in males only (Supplemental Table 1).Fig. 1. Comparison of muscle fiber composition across groups. *Significant at P < .05;
**Significant at P < .01.Quadriceps Muscle Fiber Type Composition
Figure 1 shows the proportion of type I muscle fibers across
groups. In comparison with nonsarcopenic controls, a significantly
lower proportion of type I fibers was found in both sarcopenic (26.0%
vs 50.7%, P < .001) and nonsarcopenic patients with COPD (38.7 vs
50.7 %, P < .01). Furthermore, the proportion of type I fibers was
significantly lower in sarcopenic patients with COPD than non-
sarcopenic patients (P ¼ .048). Analyses in males showed similar re-
sults (Supplemental Figure 1).
The comparison of muscle fiber types CSA across groups is
shown in Figure 2. In general, patients with COPD showed a
significantly lower CSA of type IIx muscle fiber compared with
nonsarcopenic controls (3464 vs 4472 mm2; P < .05), but no differ-
ences were found across sarcopenic phenotypes in COPD. In addi-
tion, CSA of type I fibers were significantly lower in sarcopenic
patients with COPD compared with nonsarcopenic patients (5726 vs7879 mm2; P < .05). No significant differences were found in CSA of
type I/IIa, IIa, IIa/IIx muscle fiber, or mean CSA, although CSA of type
IIa/IIx and mean CSA tended to be lower in sarcopenic patients.
Comparisons in males showed an additional difference in CSA of
type IIa/IIx fibers, which were significantly lower in sarcopenic pa-
tients than nonsarcopenic patients (4280 vs 6411 mm2; P < .05)
(Supplemental Figure 2).
Discussion
This is the first study investigating quadriceps muscle fiber-type
characteristics in relation to sarcopenia in patients with COPD and
in healthy controls. Previous studies have already demonstrated a loss
of muscle oxidative phenotype, including a muscle fiber type I/II
shift,13,14 and selective atrophy of the type IIx fibers12 in patients with
COPD. Added to the existing knowledge, the novelty of the current
study is that it demonstrates a more pronounced decrease in oxidative
type I fiber proportion in patients with COPD and sarcopenia.
Fig. 2. Comparison of muscle fiber CSA across groups. *Significant at P < .05.
C. van de Bool et al. / JAMDA 17 (2016) 415e420418Moreover, these sarcopenic patients are characterized by selective
atrophy of the type I fibers, which seems independent of the more
generalized type II atrophy in COPD as a whole.
Applying the ASMI cut-offs in our study population revealed sar-
copenia in 31.1% of the patients with COPD and 5.8% of the healthy
control participants. A comparable proportion of sarcopenic patients
with COPD was found in a South Korean noninstitutionalized civilian
population, in which 32.8% of male and 12.2% of female patients with
COPDs were sarcopenic,25 as well as in a Brazilian COPD outpatient
clinic, inwhich sarcopeniawas observed in 39.6% of the patients.26We
recently reported a considerably higher proportion of sarcopenia in
more patients with advanced COPD eligible for a pulmonary rehabil-
itation program.8 This is not surprising as skeletal muscle weakness is
an important determinant of impaired exercise performance as
important indication for referral to pulmonary rehabilitation.
Regarding muscle fiber composition, we found a significant
decrease in CSA of type IIx fibers in the patient group compared with
the (nonsarcopenic) healthy control group, which is in line with pre-
vious reports.12,27,28 The type IIx muscle fiber atrophy was not related
to sarcopenia, as it was present in both sarcopenic and nonsarcopenic
patients. Nonetheless, CSA of type IIa/IIx fibers tended to be lower in
sarcopenic patients than in nonsarcopenic patients reaching statistical
significance in the male subgroup (Supplemental Figure 2). Multiple
disease-related triggers, occurring in isolation or combined, have been
suggested to contribute to the atrophy of type II muscle fibers in COPD.
Putative catabolic triggers include nutritional depletion, inflamma-
tion, oxidative stress, and myostatin.29,30 Nutritional depletion often
occurs in COPD and is a likely contributor to atrophy of type II fibers
based on collective findings of studies on anorexia nervosa, chronic
heart failure, AIDS, and chronic renal failure.12 In addition, themajority of patients with COPD, especially muscle-wasted patients,31
exhibit chronic low-grade inflammation with elevated circulating
concentrations of tumor necrosis factor-a, mediating muscle atrophy
via the inflammatory signaling pathway nuclear factor kB.32 Further-
more, muscle-wasted patients with COPD show elevated concentra-
tions of myostatin33 and systemic oxidative stress,34 which have also
been shown to correlate negatively with muscle mass in patients with
COPD.33,34
In addition to muscle atrophy, peripheral muscle in COPD is
characterized by a I-to-II fiber type shift, leading to an impaired
oxidative phenotype.13 Long-term disuse has been described as cata-
bolic trigger preferentially affecting type I muscle fibers.35 Indeed, our
patients with COPD displayed a decreased proportion of type I fibers
in comparison with healthy controls. Moreover, this shift was even
more pronounced in sarcopenic patients with COPD, accompanied by
a clear reduction in the CSA in the type I muscle fibers. In the litera-
ture, prolonged inactivity has indeed been described as an important
driver for sarcopenia, as the sarcopenic process seems attenuated by
higher levels of physical activity36 and effects of inactivity result in
accelerated loss of skeletal muscle and functional capacity.37
Collectively, the present findings confirm our hypothesis of a more
pronounced loss of oxidative phenotype in sarcopenic patients with
COPD and correspond with our previous finding of decreased muscle
strength and endurance in sarcopenic patients with COPD. In addition
to reduced exercise capacity,38 loss of oxidative phenotype might
potentially acceleratemusclewasting. First, a shift towardmore type II
fibers will lead to an increased reliance on glycolytic metabolism,
contributing to metabolic inefficiency. Furthermore, type II fibers are
more susceptible to atrophying disease-related triggers as
inflammation-induced and oxidative stress-induced damage.15e17
C. van de Bool et al. / JAMDA 17 (2016) 415e420 419Moreover, fiber shifting in the vastus lateralis of patients with COPD
was recently identified as an independent predictor of mortality in
patients with severe to very severe COPD.39
Some limitations of the present study deserve discussion. Nowa-
days, the European Working Group on Sarcopenia in Older People
recommends using the presence of low physical function (strength or
performance) next to low ASMI.40 The current study design was
retrospective, restraining the availability of a functional measure
performed in each of the 3 study populations. Therefore, sarcopenia
was diagnosed based on the presence of low ASMI only. None of the
subgroups was confined to a single study population and because only
standardized and routine measurements were studied, we are confi-
dent that this did not introduce selection bias. Furthermore, the study
design was cross-sectional, and although this was suitable to answer
the current research question, longitudinal studies monitoring how
fiber type alterations develop as the muscle wasting process pro-
gresses are required to disentangle the cause and consequence. Finally
the unequal gender distribution between the subgroups does not rule
out putative gender differences in the association between sarcopenia
and loss of oxidative phenotype.
The current study supports exercise training programs for patients
with COPD that combine resistance and aerobic exercises as
commonly applied in pulmonary rehabilitation, or combining endur-
ance exercise with anabolics. Myostatin inhibitors, for example, are
currently investigated as promising anabolic pharmacologic agents for
restoring muscle mass. However, some studies suggest that inhibition
of myostatin might have detrimental effects on the oxidative capacity
of muscle fibers,41e44 which could be combatted by a multimodal
intervention approach.
In conclusion, this study shows evidence for a more pronouncedly
decreased type I fiber proportion in sarcopenic patients with COPD.
These findings could reflect a cross-talk between muscle mass and
oxidative phenotype regulation, which might accelerate the muscle
wasting process in patients with COPD.Supplementary Data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.jamda.2015.12.094.References
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